Clinical Trials Logo
  1. Home
  2. Grade 3b Follicular Lymphoma
  3. NCT02927717

An Italian Experience on Grade 3b Follicular Lymphoma — FL3b-Oss-2015  

Grade 3b Follicular Lymphoma Clinical Trial

Official title:
An Italian Experience on Grade 3b Follicular Lymphoma

Clinical Trial Summary

Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.

Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02927717
Study type Observational
Source Azienda Ospedaliera Città della Salute e della Scienza di Torino
Contact Barbara Botto, MD
Phone +390116334553
Email bbotto@cittadellasalute.to.it
Status Not yet recruiting
Phase N/A
Start date October 2016
Completion date May 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05890352 - Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Phase 2
Recruiting NCT06026319 - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Phase 1
Completed NCT02541565 - Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma Phase 1
Recruiting NCT04799275 - Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Phase 2/Phase 3
Terminated NCT04156828 - Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Phase 1
Recruiting NCT05583149 - Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas Phase 2
Recruiting NCT05633615 - Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Phase 2
Active, not recruiting NCT03150329 - Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Phase 1
Recruiting NCT05455697 - Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Phase 1/Phase 2
Approved for marketing NCT05733650 - Expanded Access Program for Epcoritamab